Stock Price Forecast

May 2, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Heat Biologics Inc chart...

About the Company

Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.

CEO

Jeffrey Wolf

Exchange

NYSE MKT LLC

Website

www.heatbio.com

$2M

Total Revenue

39

Employees

$60M

Market Capitalization

-1.69

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $HTBX News

Heat Biologics Takes Beating After Pricing $12 Million Stock Offering

5y ago, source: TheStreet.com

Heat Biologics Inc. nosedived after the Durham, North Carolina-based biopharmaceutical company filed for a share offering pricing expected to hit $12 million. Heat Biologics Inc. nosedived after ...

Heat Biologics (FRA:1HB) Price Target Decreased by 14.01% to 8.44

10mon ago, source: Hosted on MSN

The average one-year price target for Heat Biologics has been revised to 8.44 / share.This is an decrease of 14.01% from the prior estimate of 9.82 dated April 6, 2023. The price target is an ...

Harnessing the immune system to turn cold tumors hot

3y ago, source: Nature

To address this unmet medical need, Heat Biologics is developing drug candidates that turn immunologically ‘cold’ tumors ‘hot’ with a fresh infiltrate of CD8 + killer T cells, enhancing ...

Scorpius Holdings, Inc. Announces Closing of Public Offering

6d ago, source:

Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the closing of its previously ...

Synthetic Biologics (NYSEMKT: SYN)

3d ago, source: The Motley Fool

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product ...

Heat 2: Everything We Know About The Michael Mann Sequel

on MSN ago, source:

At some point soon, we'll get Heat 2, the long-awaited follow-up to Mann’s sprawling crime epic. But before the upcoming book ...

Theriva Biologics Inc TOVX

5d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

AbCellera Biologics (NASDAQ: ABCL)

3d ago, source: The Motley Fool

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies ...

ADMA Biologics Inc ADMA

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Q4 2023 ADMA Biologics Inc Earnings Call

19d ago, source: Yahoo Finance

Skyler Bloom; Senior Director, Corporate Strategy & Business Development; ADMA Biologics, Inc. Adam Grossman; Founder, Director, President & CEO; ADMA Biologics, Inc ...

IVBIY Innovent Biologics, Inc.

14d ago, source: Seeking Alpha

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and ...

Scorpius Holdings, Inc. Announces Pricing of Public Offering

10d ago, source:

ThinkEquity is acting as sole book-running manager for the offering.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...